Chargement en cours...
Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
We performed a pilot-study on pegylated liposomal doxorubicin (PLD) for advanced hepatocellular carcinoma. Seventeen patients received 40 mg/m(2) PLD intravenously every 4 weeks. A clinical benefit response was achieved in 50% (complete remission 7%, minor remission 7%, stable disease 36%). Toxiciti...
Enregistré dans:
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Nature Publishing Group
2001
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2364023/ https://ncbi.nlm.nih.gov/pubmed/11747325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2001.2149 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|